Industry news update covering April 2021

References

• 1. Transdermal drug delivery devices – medical devices pipeline assessment, 2020. http://www.researchandmarkets.com
  Google Scholar
• 2. Drug delivery in central nervous system (CNS) diseases: 2019 technologies, markets & companies - forecast to 2028. http://www.researchandmarkets.com
  Google Scholar
• 3. Smart pill market by pills and components, tools and technologies, production method, distribution channels, and diagnostics 2021–2026. http://www.researchandmarkets.com
  Google Scholar
• 4. CURE pharmaceutical reports increase in revenue to $7.7 million on a pro forma basis in 2020. curepharmaceutical.com/press-releases/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020/
  Google Scholar
• 5. GH research announces closing of $125 million oversubscribed series B financing. http://www.prnewswire.com/news-releases/gh-research-announces-closing-of-125-million-oversubscribed-series-b-financing-301266980.html
  Google Scholar
• 6. Impel NeuroPharma announces pricing of $80.0 million initial public offering. impelnp.com/2021/04/22/impel-neuropharma-announces-pricing-of-80-0-million-initial-public-offering/
  Google Scholar
• 7. Elektrofi enters global collaboration and license agreement with Argenx to explore new subcutaneous product formulations. http://www.elektrofi.com/news-1/2021/4/20/elektrofi-enters-global-collaboration-and-license-agreement-with-argenx-to-explore-new-subcutaneous-product-formulations
  Google Scholar
• 8. Brooklyn ImmunoTherapeutics acquires license for mRNA technology platform to develop genetically edited cells to treat multiple cancers, blood and other disorders. http://www.brooklynitx.com/brooklyn-immunotherapeutics-acquires-license-mrna-technology-platform-to-develop-genetically-edited-cells-to-treat-multiple-cancers-blood-and-other-disorders/
  Google Scholar
• 9. Progenity and Ionis Pharmaceuticals enter into agreement to evaluate Progenity's ingestible oral Biotherapeutics Technology for delivery of antisense therapies. investors.progenity.com/news-releases/news-release-details/progenity-and-ionis-pharmaceuticals-enter-agreement-evaluate
  Google Scholar
• 10. Kindeva Drug Delivery and Cambridge Healthcare Innovations Limited to collaborate on development of novel dry-powder inhaler product. kindevadd.com/news/dpi/
  Google Scholar
• 11. HTL Biotechnology and Echelon Biosciences Inc. Announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools. htlbiotech.com/wp-content/uploads/2021/04/NR_HTL-Echelon_partnership_EN.pdf
  Google Scholar
• 12. Nanoform and Aprecia collaborate to advance 3D printed nanomedicines. nanoform.com/en/nanoform-and-aprecia-collaborate-to-advance-3d-printed-nanomedicines/
  Google Scholar
• 13. Zosano Pharma confirms plan to move forward with pharmacokinetic study following protocol review by FDA. https://ir.zosanopharma.com/news-releases/news-release-details/zosano-pharma-confirms-plan-move-forward-pharmacokinetic-study
  Google Scholar
• 14. United Therapeutics announces submission of Tyvaso DPI™ new drug application to FDA. https://ir.unither.com/news/press-releases/press-release-details/2021/United-Therapeutics-Announces-Submission-of-Tyvaso-DPI-New-Drug-Application-to-FDA/default.aspx
  Google Scholar
• 15. Liquidia resubmits new drug application for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension. https://liquidia.com/news-releases/news-release-details/liquidia-resubmits-new-drug-application-liq861-treprostinil
  Google Scholar
• 16. Celltrion Healthcare receives positive CHMP opinion for subcutaneous formulation of infliximab, Remsima^® SC, for direct use of subcutaneous therapy without IV loading in adults with rheumatoid arthritis. http://www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=470&pagenumber=1&keyword=&keyword_type=
  Google Scholar
• 17. FDA approves Xolair (omalizumab) prefilled syringe for self-injection across all indications. http://www.gene.com/media/press-releases/14904/2021-04-12/fda-approves-xolair-omalizumab-prefilled
  Google Scholar
• 18. Lyra Theraeutics presents postitive full data set from LANTERN Phase II study of LYR-210 at COSM 2021 VIRTUA. https://investors.lyratherapeutics.com/news-releases/news-release-details/lyra-therapeutics-presents-positive-full-data-set-lantern-phase
  Google Scholar
• 19. Jubilant Pharma announces the development of a novel oral formulation of remdesivir with successful completion of safety and pharmacokinetic/absorption studies in animals and healthy human volunteers. http://www.jubilantpharma.com/news-room/press-release
  Google Scholar
• 20. CT143 - pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma. http://www.abstractsonline.com/pp8/#!/9325/presentation/5214
  Google Scholar
• 21. Reker D, Rybakova Y, Kirtane AR et al. Computationally guided high-throughput design of self-assembling drug nanoparticles. Nat. Nanotechnol. doi:10.1038/s41565-021-00870-y (2021) (Epub ahead of print).
  MedlineGoogle Scholar
• 22. Zhao D, Tao W, Li S et al. Apoptotic body–mediated intercellular delivery for enhanced drug penetration and whole tumor destruction. Sci. Adv. 7(16), eabg0880 (2021).
  Medline CASGoogle Scholar
• 23. Aguilar-Perez KM, Medina DI, Narayanan J, Parra-Saldivar R, Iqbal HMN. Synthesis and nano-sized characterization of bioactive oregano essential oil molecule-loaded small unilamellar nanoliposomes with antifungal potentialities. Molecules 26(10), 1–16 (2021).
  Google Scholar
• 24. Fine D, Grattoni A, Zabre E, Hussein F, Ferrari M, Liu X. A low-voltage electrokinetic nanochannel drug delivery system. Lab Chip 11(15), 2526–2534 (2011).
  Medline CASGoogle Scholar